Table 1.
Clinical characteristics of patients
| Characteristics | Individuals with recurrent wheezing | Wheezing individuals with asthmatic diagnosis | |
|---|---|---|---|
| Groups | Infancy (0–2 years old) | Pre-school children (2–5 years old) | School children (5–12 years old) |
| Age on first wheezing attack (years old) | 0.42 (0.25–0.63) | 1.63 (1–2.5) | 4 (3–5.17) |
| Duration of symptoms (years) | 0.33 (0.25–0.92) | 1 (0.63–2) | 2 (1–3) |
| Hospitalization times due to wheezing attack | 2 (1–2) | 2 (2–2.25) | 3 (2–4) |
| FEV1 | |||
| FEV1 predicted (L) | - | 1.69 (1.12–2.3) | |
| FEV1 pre-treatment (L) | - | 1.23 (0.8–1.38) | |
| FEV1 pre-treatment (% predicted) | - | 72.4 (67.3–76.1) | |
| FEV1/FVC ratio | |||
| FEV1/FVC ratio predicted | - | 0.8512 (0.8438–0.8539) | |
| FEV1/FVC ratio pre-treatment | - | 0.7008 (0.6828–0.7059) | |
| FEV1/FVC ratio pre-treatment (% predicted) | - | 81.7 (80.1–83.4) | |
| In vitro allergen test | - | Various allergens are confirmed such as soybean, mite collection, codfish, lobster, fan-shell, shrimp and house dust. | |
Values in Table 1 are presented as medians (IQRs), IQRs interquartile ranges. Medications in the table refer to drug treatment before sample collections. In vitro allergen test and detection of lung function such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) are not available for children less than 5 years old